Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s)
The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Abstract
Rationale To increase subtype selectivity and provide a novel means to alter receptor function, we discovered and characterization potentiators for the metabotropic glutamate 2 receptor (mGlu2).Methods and results A class of 3-pyridylmethylsulfonamides (e.g., 3-MPPTS; 2,2,2-trifluoro-N-[3-(2-methoxyphenoxy)phenyl]-N-(3-pyridinylmethyl)-ethanesulfonamide) were found to be potent, subtype-selective potentiators of human and rat mGlu2. The sulfonamides increased agonist potency in functional assays but did not displace orthosteric radiolabeled antagonist or agonist binding to cloned mGlu2 receptors. Rather, the modulators increased the affinity of most of the orthosteric agonists including glutamate, DCG-IV (2S,2'R,3'R)-2-(2',3'-dicarboxylcyclopropyl)glycine), and LY354740 (1S,2S,5R,6S-2-aminobicyclo[3.1.0]hexane-2,6-bicaroxylate monohydrate). In striatal brain slices, LY354740 inhibited evoked excitatory postsynaptic potentials (EPSPs) equally well following either a low- (0.06 Hz) or high (4 Hz)-frequency stimulation of corticostriatal afferents. In contrast, the mGlu2 potentiator cyPPTS (2,2,2-trifluoro-N-[3-(cyclopentyloxy)phenyl]-N-(3-pyridinylmethyl)-ethanesulfonamide) inhibited striatal EPSPs only at higher frequencies of stimulation (2 and 4 Hz). Several sulfonamides including 4-MPPTS, 4-APPES (N-[4-(4-carboxamidophenoxy)phenyl]-N-(3-pyridinylmethyl)-ethanesulfonamide hydrochloride monohydrate) and/or CBiPES N-[4'-cyano-biphenyl-3-yl)-N-(3-pyridinylmethyl)-ethanesulfonamide hydrochloride) were tested in mGlu2/3 agonist-sensitive rodent model(s) of anxiety and psychosis. As seen with LY354740, both 4-MPPTS and 4-APPES were efficacious in a rat fear-potentiated startle paradigm. Likewise in mice, CBiPES attenuated a stress-induced hyperthermia and PCP-induced hyperlocomotor activity. Furthermore, CBiPES mediated alteration in PCP-induced hyperlocomotor activity was sensitive to mGlu2/3 antagonist pretreatment.Conclusions Taken together, the data indicate mGlu2 receptor potentiators have a unique use-dependent effect on presynaptic glutamate release, and show efficacy in several mGlu2/3-sensitive animal models of psychiatric disorders.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, preclinical rodent studies have established a strong link between glutamate regulation and anxiety (Domi et al, 2016;Donahue et al, 2014;Johnson et al, 2005;McGowan et al, 2017;Walker and Davis, 2002).”
From Ketamine for Social Anxiety Disorder: A Randomized, Placebo-Controlled Crossover Trial (2018) · cites this paper as Johnson et al, 2005
Citations
Cites
Yung-Chi, C., & Prusoff, W. H. (1973) · Biochemical Pharmacology · doi:10.1016/0006-2952(73)90196-2 · Cited by 12,922 · cited 2×
“The affinity constants for orthosteric agonists, with and without 3-MPPTS present, were calculated using the Cheng and Prusoff equation (Ki=IC50/(1+[ (3)H-DCG-IV]/Kd)) (Cheng and Prusoff 1973) and the IC50 from a four-parameter fit of the displacement curves.”
Recent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904 · cited 1×
“Atypical antipsychotics are particularly effective in this model, and many of the behavioral consequences of PCP intoxication appear to be very similar to those seen in psychosis (for reviews, see Halberstadt 1995; Javitt and Zukin 1991).”
G Protein-Coupled Receptor Allosterism and Complexing
Christopoulos, A., & Kenakin, T. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.2.323 · Cited by 931 · cited 2×
“2b) (Christopoulos and Kenakin 2002) resulted in a equilibrium constant for potentiation (Kpt) of 144±43 nM (mean± SE, df=12, R2=0.92) and an α potentiation value (a measure of the degree of positive modulation) of 3.31±0.03.”
InfluentialPetralia, R. S., Wang, Y.-X., Niedzielski, A. S., & Wenthold, R. J. (1996) · Neuroscience · doi:10.1016/0306-4522(95)00533-1 · Cited by 579 · cited 2×
“Frequency-dependent modulation of glutamatergic corticostriatal synaptic transmission by cyPPTS Previous immunocytochemical (Petralia et al. 1996) and electrophysiological (Lovinger and McCool 1995) studies have suggested that mGlu2 receptors are located presynaptically on cortical glutamatergic…”
Lorrain, D. S., Baccei, C. S., Bristow, L. J., Anderson, J. J., & Varney, M. A. (2003) · Neuroscience · doi:10.1016/s0306-4522(02)00652-8 · Cited by 432 · cited 2×
“2002; Kim and Vezina 2002; Swanson and Schoepp 2002) and rearing behaviors, as well as increasing the release of prefrontal cortex dopamine and other limbic nuclei monoamines (Cartmell et al. 2000d,e, 2001; Lorrain et al. 2003).”
Monn, J. A., Valli, M. J., Massey, S. M., Wright, R. A., Salhoff, C. R., Johnson, B. G., Howe, T., Alt, C. A., Rhodes, G. A., Robey, R. L., et al. (1997) · Journal of Medicinal Chemistry · doi:10.1021/jm9606756 · Cited by 390 · cited 8×
“Previous work has shown that mGlu2/3 orthosteric agonists such as LY354740 and LY379268 are efficacious in a rat fear-potentiated startle paradigm (Helton et al. 1998; Monn et al. 1997; Tizzano et al. 2002; Walker and Davis 2002).”
InfluentialSelf-citationThe role of amygdala glutamate receptors in fear learning, fear-potentiated startle, and extinction
Walker, D. L., & Davis, M. (2002) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(01)00698-0 · Cited by 355 · cited 4×
“Previous work has shown that mGlu2/3 orthosteric agonists such as LY354740 and LY379268 are efficacious in a rat fear-potentiated startle paradigm (Helton et al. 1998; Monn et al. 1997; Tizzano et al. 2002; Walker and Davis 2002).”
InfluentialMonn, J. A., Valli, M. J., Massey, S. M., Hansen, M. M., Kress, T. J., Wepsiec, J. P., Harkness, A. R., Grutsch, Wright, R. A., Johnson, B. G., et al. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm980616n · Cited by 293 · cited 1×
“An example of this is found with the Group II mGlu selective agonists such as LY354740 (1S,2S,5R,6S-2-aminobicyclo [3.1.0]hexane-2,6-bicaroxylatemonohydrate), and LY379268 (1R,4R,5S,6R-4-amino-oxabicyclo[3.1.0]hexane-4,6-dicarboxylic acid) (Monn et al. 1999; Monn et al. 1997).”
InfluentialSelf-citationVisualizing unstained neurons in living brain slices by infrared DIC-videomicroscopy
Dodt, H.-U., & Zieglgänsberger, W. (1990) · Brain Research · doi:10.1016/0006-8993(90)90380-t · Cited by 291 · cited 2×
“…mounted on an upright microscope (BX50WI, Olympus Corporation) and continuously superfused (2–3 ml/min) with the oxygenated saline solution maintained at 30±0.2°C. Differential interference videomicroscopy (Dodt and Zieglgansberger 1990) was used to visualize medium spiny neurons in the striatum.”
InfluentialHelton, D. R., Tizzano, J. P., Monn, J. A., Schoepp, D. D., & Kallman, M. J. (1998) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37253-2 · Cited by 279 · cited 6×
“For instance, LY354740 and/or LY379268 have been shown to be efficacious in anxiety models such as: fearinduced potentiated startle (Helton et al. 1998; Monn et al. 1997; Tizzano et al. 2002; Walker and Davis 2002), elevated plus maze (Ferris et al. 2001; Helton et al. 1998; M. P. Johnson (*) .”
InfluentialSelf-citationCartmell, J., Monn, J. A., & Schoepp, D. D. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35084-0 · Cited by 269 · cited 3×
“Previously, mGlu2/3 agonists have shown efficacy in both rat and mouse models of PCP-induced locomotor responses (Cartmell et al. 1999, 2000a,b,c; Clark et al. 2002).”
Self-citationMarino, M. J., Williams, D. L., O'Brien, J. A., Valenti, O., McDonald, T. P., Clements, M. K., Wang, R., DiLella, A. G., Hess, J. F., Kinney, G. G., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1835724100 · Cited by 240 · cited 2×
“2003), and a group III receptor mGlu4 (Maj et al. 2003; Marino et al. 2003; Mathiesen et al. 2003).”
Urwyler, S., Mosbacher, J., Lingenhoehl, K., Heid, J., Hofstetter, K., Froestl, W., Bettler, B., & Kaupmann, K. (2001) · PubMed · Cited by 239
Knoflach, F., Mutel, V., Jolidon, S., Kew, J. N. C., Malherbe, P., Vieira, E., Wichmann, J., & Kemp, J. A. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.231358298 · Cited by 238 · cited 4×
“This includes positive allosteric modulators of the Group I receptors mGlu1 (Knoflach et al. 2001; Wichmann et al. 2002) and mGlu5 (Goudet et al.”
InfluentialLovinger, D. M., & McCool, B. A. (1995) · Journal of Neurophysiology · doi:10.1152/jn.1995.73.3.1076 · Cited by 234 · cited 2×
“1996) and electrophysiological (Lovinger and McCool 1995) studies”
Urwyler, S., Mosbacher, J., Lingenhoehl, K., Heid, J., Hofstetter, K., Froestl, W., Bettler, B., & Kaupmann, K. (2001) · Molecular Pharmacology · doi:10.1124/mol.60.5.963 · Cited by 219 · cited 4×
“Voltage-dependent Na+ currents were blocked by inclusion of QX314 (1 mM) in the patch pipette solution. γ-Aminobutyric acid (GABA) synaptic transmission was eliminated using the selective antagonists of GABAA and GABAB receptors, bicuculline methiodide (1–2 μM) and SCH59011 (2 μM), respectively.”
InfluentialA Family of Highly Selective Allosteric Modulators of the Metabotropic Glutamate Receptor Subtype 5
O’Brien, J. A., Lemaire, W., Chen, T.-B., Chang, R. S. L., Jacobson, M. A., Ha, S. N., Lindsley, C. W., Schaffhauser, H. J., Sur, C., Pettibone, D. J., et al. (2003) · Molecular Pharmacology · doi:10.1124/mol.64.3.731 · Cited by 209 · cited 4×
“This includes positive allosteric modulators of the Group I receptors mGlu1 (Knoflach et al. 2001; Wichmann et al. 2002) and mGlu5 (Goudet et al. 2004; O’Brien et al. 2003; Williams et al. 2003), and a group III receptor mGlu4 (Maj et al. 2003; Marino et al. 2003; Mathiesen et al. 2003).”
InfluentialLY354740, an mGlu2/3 Receptor Agonist as a Novel Approach to Treat Anxiety/Stress
Schoepp, D. D., Wright, R. A., Levine, L. R., Gaydos, B., & Potter, W. Z. (2003) · Stress · doi:10.1080/1025389031000146773 · Cited by 207 · cited 2×
“Most significantly, the mGlu2/3 agonists are anxiolytic in human paradigms such as potentiated startle (Grillon et al. 2003) and CO2-induced panic attacks (Schoepp et al. 2003).”
Self-citationMaj, M. (2003) · Neuropharmacology · doi:10.1016/s0028-3908(03)00271-5 · Cited by 197 · cited 2×
“2003), and a group III receptor mGlu4 (Maj et al. 2003; Marino et al. 2003; Mathiesen et al. 2003).”
Heptahelical domain of metabotropic glutamate receptor 5 behaves like rhodopsin-like receptors
Goudet, C., Gaven, F., Kniazeff, J., Vol, C., Liu, J., Cohen-Gonsaud, M., Acher, F., Prézeau, L., & Pin, J. P. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0304699101 · Cited by 196 · cited 2×
“This includes positive allosteric modulators of the Group I receptors mGlu1 (Knoflach et al. 2001; Wichmann et al. 2002) and mGlu5 (Goudet et al. 2004; O’Brien et al. 2003; Williams et al. 2003), and a group III receptor mGlu4 (Maj et al. 2003; Marino et al. 2003; Mathiesen et al. 2003).”
Grillon, C., Cordova, J., Levine, L. R., & Morgan, III (2003) · Psychopharmacology · doi:10.1007/s00213-003-1444-8 · Cited by 185 · cited 4×
“In fear-potentiated startle response paradigms, mGlu2/3 agonists such as LY354740 has demonstrated efficacy in both rodents (Helton et al. 1998) and humans (Grillon et al. 2003).”
InfluentialJohnson, M. P., Baez, M., Jagdmann, G. E., Britton, T. C., Large, T. H., Callagaro, D. O., Tizzano, J. P., Monn, J. A., & Schoepp, D. D. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm034015u · Cited by 182 · cited 10×
“In a previous report (Johnson et al. 2003), we showed that a mGlu2 potentiator, 4-MPPTS, was also efficacious in this anxiety model, and that the efficacy could be prevented by pretreatment of an mGlu2/3 antagonist.”
InfluentialSelf-citationMathiesen, J. M., Svendsen, N., Bräuner‐Osborne, H., Thomsen, C., & Ramirez, M. T. (2003) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705159 · Cited by 173 · cited 2×
“2003), and a group III receptor mGlu4 (Maj et al. 2003; Marino et al. 2003; Mathiesen et al. 2003).”
Schaffhauser, H., Rowe, B. A., Morales, S., Chavez-Noriega, L. E., Yin, R., Jachec, C., Rao, S. P., Bain, G., Pinkerton, A. B., Vernier, J.-M., et al. (2003) · Molecular Pharmacology · doi:10.1124/mol.64.4.798 · Cited by 160 · cited 5×
“Similarly, recent reports have described positive allosteric modulators of the mGlu2 receptor discovered at Lilly Research Laboratories (Johnson et al. 2003; Schaffhauser et al. 2003).”
InfluentialA model to measure anticipatory anxiety in mice?
Borsini, F., Lecci, A., Volterra, G., & Meli, A. (1989) · Psychopharmacology · doi:10.1007/bf00444693 · Cited by 153 · cited 2×
“Stress-induced hyperthermia in mice The ability of stress to induce a transient rise in body temperature in DBA/2 mice as previously described (Borsini et al. 1989) was monitored as follows.”
Gasparini, F. (2002) · Current Opinion in Pharmacology · doi:10.1016/s1471-4892(01)00119-9 · Cited by 146 · cited 3×
“The Group I antagonists, such as MPEP and CPCCOEt (Brauner-Osborne et al. 1999; Gasparini et al. 2002) (Kuhn et al. 2002), and the more recently reported GABAB (Urwyler et al. 2001), mGlu1 and mGlu5 potentiators (Knoflach et al. 2001; O’Brien et al. 2003; Wichmann et al. 2002; Williams et al.…”
Spooren, W. P. J. M., Schoeffter, P., Gasparini, F., Kuhn, R., & Gentsch, C. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(01)01562-x · Cited by 140 · cited 5×
“…hyperthermia anxiety model Previous work has shown that the mGlu2/3 agonist LY 354740 is efficacious in stress-induced hyperthermia models (Spooren et al. 2002), albeit requiring doses higher than those needed to show efficacy in the rat fear-potentiated Values are mean±SEM (n). a3 μM…”
InfluentialKłodzińska, A., Chojnacka-Wójcik, E., Pałucha-Poniewiera, A., Brański, P., Popik, P., & Pilc, A. (1999) · Neuropharmacology · doi:10.1016/s0028-3908(99)00066-0 · Cited by 133 · cited 2×
“7a) associated with an exploration in a novel environment as has also been previously reported with mGlu2/3 agonists and is absent in mGlu2 knockout mice (Klodzinska et al. 1999; Spooren et al. 2000).”
Cartmell, J., Monn, J. A., & Schoepp, D. D. (2000) · Psychopharmacology · doi:10.1007/s002130050072 · Cited by 121 · cited 7×
“LY354740 and/or LY379268 are active in reversing psychostimulant (e.g., PCP and amphetamine)-mediated locomotor ( Cartmell et al. 1999, 2000a, b,c; Clark et al. 2002; Kim and Vezina 2002; Swanson and Schoepp 2002) and rearing behaviors, as well as increasing the release of prefrontal cortex dopamine and other limbic n…”
InfluentialSelf-citationShekhar, A., & Keim, S. R. (2000) · Neuropharmacology · doi:10.1016/s0028-3908(99)00215-4 · Cited by 121 · cited 2×
“: +1-317-2776581 Fax: +1-317-2765546 Monn et al. 1997), stress-induced hyperthermia and monoamine release (Spooren et al. 2002; Swanson et al. 2004), and lactate-induced anxiety (Shekhar and Keim 2000).”
A model for the functioning of family 3 GPCRs
Parmentier, M. (2002) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(02)02016-3 · Cited by 114 · cited 2×
“Parmentier et al. (2002) have recently hypothesized that potentiators acting at class C GPCRs, such as mGlu2, would increase both the apparent potency and/or maximal effect of an agonist.”
The Phencyclidine-Glutamate Model of Schizophrenia
Halberstadt, A. L. (1995) · Clinical Neuropharmacology · doi:10.1097/00002826-199506000-00004 · Cited by 104 · cited 2×
“many of the behavioral consequences of PCP intoxication appear to be very similar to those seen in psychosis (for reviews, see Halberstadt 1995; Javitt and Zukin 1991).”
Spooren, W. P. J. M., Gasparini, F., van der Putten, H., Koller, M., Nakanishi, S., & Kuhn, R. R. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00269-7 · Cited by 94 · cited 5×
“novel environment as has also been previously reported with mGlu2/3 agonists and is absent in mGlu2 knockout mice (Klodzinska et al. 1999; Spooren et al. 2000).”
InfluentialThe mGlu2/3 receptor agonist LY379268 selectively blocks amphetamine ambulations and rearing
Cartmell, J., Monn, J. A., & Schoepp, D. D. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00423-4 · Cited by 91 · cited 4×
“Previously, mGlu2/3 agonists have shown efficacy in both rat and mouse models of PCP-induced locomotor responses (Cartmell et al. 1999, 2000a,b,c; Clark et al. 2002).”
InfluentialSelf-citationPicconi, B. (2002) · Brain · doi:10.1093/brain/awf269 · Cited by 84 · cited 1×
“Activation of these presynaptic receptors with selective group II agonists can suppress excitatory corticostriatal synaptic transmission (Lovinger andMcCool 1995; Picconi et al. 2002).”
Cartmell, J., Adam, G., Chaboz, S., Henningsen, R. A., Kemp, J. A., Klingelschmidt, A., Metzler, V., Monsma, F. J., Schaffhauser, H., Wichmann, J., et al. (1998) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0701647 · Cited by 80 · cited 3×
“Effects on orthosteric agonist radioligand binding In the mGlu2 clonal cell line, the agonist, 3H-DCG-IV, specifically bound to the glutamate site of the mGlu2 receptor as previously reported (Cartmell et al. 1998).”
InfluentialTizzano, J. P., Griffey, K. I., & Schoepp, D. D. (2002) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(02)00850-x · Cited by 75 · cited 5×
“For instance, LY354740 and/or LY379268 have been shown to be efficacious in anxiety models such as: fearinduced potentiated startle (Helton et al. 1998; Monn et al. 1997; Tizzano et al. 2002; Walker and Davis 2002), elevated plus maze (Ferris et al. 2001; Helton et al. 1998; M. P. Johnson (*) .”
InfluentialSelf-citationCartmell, J., Perry, K. W., Salhoff, C. R., Monn, J. A., & Schoepp, D. D. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0751147.x · Cited by 62 · cited 5×
“…locomotor (Cartmell et al. 1999, 2000a,b,c; Clark et al. 2002; Kim and Vezina 2002; Swanson and Schoepp 2002) and rearing behaviors, as well as increasing the release of prefrontal cortex dopamine and other limbic nuclei monoamines (Cartmell et al. 2000d,e, 2001; Lorrain et al. 2003).”
InfluentialSelf-citationCartmell, J., Monn, J. A., & Schoepp, D. D. (2000) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s002109900151 · Cited by 61 · cited 4×
“Previously, mGlu2/3 agonists have shown efficacy in both rat and mouse models of PCP-induced locomotor responses (Cartmell et al. 1999, 2000a,b,c; Clark et al. 2002).”
InfluentialSelf-citationSwanson, C. J., & Schoepp, D. D. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.038422 · Cited by 59 · cited 2×
“, PCP and amphetamine)-mediated locomotor (Cartmell et al. 1999, 2000a,b,c; Clark et al. 2002; Kim and Vezina 2002; Swanson and Schoepp 2002) and rearing behaviors, as well as increasing the release of prefrontal cortex dopamine and other limbic nuclei monoamines (Cartmell et al.”
Self-citationKim, J.-H., & Vezina, P. (2002) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(02)00827-4 · Cited by 54 · cited 2×
“, PCP and amphetamine)-mediated locomotor (Cartmell et al. 1999, 2000a,b,c; Clark et al. 2002; Kim and Vezina 2002; Swanson and Schoepp 2002) and rearing behaviors, as well as increasing the release of prefrontal cortex dopamine and other limbic nuclei monoamines (Cartmell et al.”
Barda, D. A., Wang, Z., Britton, T. C., Henry, S. S., Jagdmann, G. E., Coleman, D. S., Johnson, M. P., Andis, S. L., & Schoepp, D. D. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.04.017 · Cited by 54 · cited 2×
“…hydrochloride monohydrate), and CBiPES (N-[4′-cyano-biphenyl-3-yl)-N-(3-pyridinylmethyl)-ethanesulfonamide hydrochloride) were synthesized at Lilly Research laboratories as previously described (Barda et al. 2004; Johnson et al. 2003).”
Self-citationCartmell, J., Perry, K. W., Salhoff, C. R., Monn, J. A., & Schoepp, D. D. (2001) · Neuropharmacology · doi:10.1016/s0028-3908(01)00034-x · Cited by 51
Self-citationGroup 2 metabotropic glutamate receptors induced long term depression in mouse striatal slices
Kahn, L., Alonso, G., Robbe, D., Bockaert, J., & Manzoni, O. J. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(01)02397-7 · Cited by 47 · cited 1×
“Previous studies have demonstrated that mGlu2/3 receptor agonists can suppress glutamatergic excitatory responses in striatal neurons (Kahn et al. 2001).”
Kühn, R., Pagano, A., Stoehr, N., Vranesic, I., Flor, P. J., Lingenhöhl, K., Spooren, W. P. J. M., Gentsch, C., Vassout, A., Pilc, A., et al. (2002) · Amino Acids · doi:10.1007/s00726-001-0130-6 · Cited by 47 · cited 2×
“The Group I antagonists, such as MPEP and CPCCOEt (Brauner-Osborne et al. 1999; Gasparini et al. 2002) (Kuhn et al. 2002), and the more recently reported GABAB (Urwyler et al. 2001), mGlu1 and mGlu5 potentiators (Knoflach et al. 2001; O’Brien et al. 2003; Wichmann et al. 2002; Williams et al.…”
Ferris, P., Seward, E. M., & Dawson, G. R. (2001) · Journal of Psychopharmacology · doi:10.1177/026988110101500203 · Cited by 46 · cited 1×
“For instance, LY354740 and/or LY379268 have been shown to be efficacious in anxiety models such as: fearinduced potentiated startle (Helton et al. 1998; Monn et al. 1997; Tizzano et al. 2002; Walker and Davis 2002), elevated plus maze (Ferris et al. 2001; Helton et al. 1998; M. P. Johnson (*) .”
Swanson, C. J., Perry, K. W., & Schoepp, D. D. (2004) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.02125.x · Cited by 44 · cited 1×
“: +1-317-2776581 Fax: +1-317-2765546 Monn et al. 1997), stress-induced hyperthermia and monoamine release (Spooren et al. 2002; Swanson et al. 2004), and lactate-induced anxiety (Shekhar and Keim 2000).”
Self-citationCartmell, J., Salhoff, C. R., Perry, K. W., Monn, J. A., & Schoepp, D. D. (2000) · Brain Research · doi:10.1016/s0006-8993(00)03067-5 · Cited by 44 · cited 4×
“Previously, mGlu2/3 agonists have shown efficacy in both rat and mouse models of PCP-induced locomotor responses (Cartmell et al. 1999, 2000a,b,c; Clark et al. 2002).”
InfluentialSelf-citationEffects of the mGlu2/3 receptor agonist LY379268 on motor activity in phencyclidine-sensitized rats
Clark, M., Johnson, B. G., Wright, R. A., Monn, J. A., & Schoepp, D. D. (2002) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(02)00848-1 · Cited by 37 · cited 3×
“Previously, mGlu2/3 agonists have shown efficacy in both rat and mouse models of PCP-induced locomotor responses (Cartmell et al. 1999, 2000a,b,c; Clark et al. 2002).”
Self-citationWichmann, J., Bleicher, K., Vieira, E., Woltering, T. J., Knoflach, F., & Mutel, V. (2002) · Il Farmaco · doi:10.1016/s0014-827x(02)01283-1 · Cited by 32 · cited 4×
“This includes positive allosteric modulators of the Group I receptors mGlu1 (Knoflach et al. 2001; Wichmann et al. 2002) and mGlu5 (Goudet et al.”
InfluentialInteraction of CPCCOEt with a chimeric mGlu1b and calcium sensing receptor
Bräuner‐Osborne, H., Jensen, A. A., & Krogsgaard‐Larsen, P. (1999) · Neuroreport · doi:10.1097/00001756-199912160-00036 · Cited by 27 · cited 3×
“The Group I antagonists, such as MPEP and CPCCOEt (Brauner-Osborne et al. 1999; Gasparini et al. 2002) (Kuhn et al. 2002), and the more recently reported GABAB (Urwyler et al. 2001), mGlu1 and mGlu5 potentiators (Knoflach et al. 2001; O’Brien et al. 2003; Wichmann et al. 2002; Williams et al.…”
Tomita, N., Murata, M., Watanabe, H., Ichikawa, T., Washiyama, K., Kumanishi, T., & Takahashi, Y. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb05203.x · Cited by 9 · cited 1×
“Previous work has shown that mGlu2/3 agonists effectively prevent this behavior, which has been hypothesized to model some of the symptoms of psychosis (Cartmell et al. 2000a,c; Tomita et al. 2000).”
Difference in mGluR5 Interaction between Positive Allosteric Modulators from Two Structural Classes
WILLIAMS, D. L., O’Brien, J. A., Lemaire, W., Chen, T., Chang, R. S. L., Jacobson, M. A., Ha, S., Wisnoski, D. D., Lindsley, C. W., Sur, C., et al. (2003) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1300.059 · Cited by 3
Cited by
Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders
Jeffrey Conn, P., Christopoulos, A., & Lindsley, C. W. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2760 · Cited by 1,063
“Furthermore, the efficacy of mGluR2 PAMs in multiple animal models that are predictive of antipsychotic activity is close to that observed with the mGluR2/3 orthosteric agonist”
ResultThe Concise Guide to PHARMACOLOGY 2013/14: G Protein‐Coupled Receptors
Alexander, S. P. H., Benson, H. E., Faccenda, E., Pawson, A. J., Sharman, J. L., Spedding, M., Peters, J. A., Harmar, A. J., & Collaborators, C. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12445 · Cited by 556
The age of anxiety: role of animal models of anxiolytic action in drug discovery
Cryan, J. F., & Sweeney, F. F. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01362.x · Cited by 316
The Role of Glutamate in Anxiety and Related Disorders
Cortese, B. M., & Phan, K. L. (2005) · CNS Spectrums · doi:10.1017/s1092852900010427 · Cited by 232
Melancon, B. J., Hopkins, C. R., Wood, M. R., Emmitte, K. A., Niswender, C. M., Christopoulos, A., Conn, P. J., & Lindsley, C. W. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201139r · Cited by 226
Metadata
- Authors
- Johnson, M. P., Barda, D., Britton, T. C., Emkey, R., Hornback, W. J., Jagdmann, G. E., McKinzie, D. L., Nisenbaum, E. S., Tizzano, J. P., & Schoepp, D. D.
- Affiliations
- Eli Lilly (United States) (US)
- Corresponding author
- Johnson, Michael P.
- Venue
- Psychopharmacology
- Published
- 2005-02-17
- Volume
- 179
- Issue
- 1
- Pages
- 271-283
- ISSN
- 0033-3158 (ISSN-L)
- 1432-2072
- OpenAlex
- W1972722155
- Cited by
- 156
- References
- 53
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 3 · 2023: 3 · 2022: 8 · 2021: 4 · 2020: 4 · 2019: 1 · 2018: 5 · 2017: 5 · 2016: 6 · 2015: 5 · 2014: 6 · 2013: 16 · 2012: 13
- FWCI
- 4.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- anxiety models, psychosis model
- MeSH terms
- Animals, Anxiety, Cyclopropanes, Glycine, Humans, Male, Mice, Inbred DBA, Mice, Inbred ICR, Motor Activity, Synaptic Transmission, Phencyclidine, Psychotic Disorders, Radioligand Assay, Rats, Sprague-Dawley, Receptors, Metabotropic Glutamate, Excitatory Amino Acid Agonists, Excitatory Postsynaptic Potentials, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.